

RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Authors: Dongsheng Yue¹; Wenxiang Wang²; Hongxu Liu³; Qixun Chen⁴; Chun Chen⁵; Lunxu Liu⁶; Peng Zhang⁷; Guofang Zhao⁸; Fan Yang⁹; Guang Han¹⁰; Ying Cheng¹¹; Bentong Yu¹²; Yue Yang¹³; Haiquan Chen¹⁴; Jie Jiang¹⁵; Bin Yao¹⁶; Shengfei Wang¹⁷; Ruihua Wang¹⁷; Wenjuan Zheng¹⁶; Changli Wang¹

Affiliations: ¹Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; ²Hunan Cancer Hospital, Hunan, China; ³Liaoning Cancer Hospital and Institute, Shenyang, China; ⁴Zhejiang Cancer Hospital, Hangzhou, China; ⁵Fujian Medical University Union Hospital, Fuzhou, China; ⁶West China Hospital, Sichuan University, Chengdu, China; ⁷Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; ⁸Ningbo No.2 Hospital, Ningbo, China; ⁹Peking University People's Hospital, Beijing, China; ¹⁰Hubei Cancer Hospital, Wuhan, China; ¹¹Jilin Cancer Hospital, Changchun, China; ¹²The First Affiliated Hospital of Nanchang University, Nanchang, China; ¹³Beijing Cancer Hospital, Beijing, China; ¹⁴Fudan University Shanghai Cancer Center, Shanghai, China; ¹⁵The First Affiliated Hospital of Xiamen University, Xiamen, China; ¹⁶BeiGene (Beijing) Co., Ltd, Beijing, China; ¹⁷BeiGene (Shanghai) Co., Ltd, Shanghai, China

ABSTRACT

Background: The RATIONALE-315 study (NCT04379635) compared the efficacy and safety of neoadjuvant TIS (anti-PD-1) plus CT and adjuvant TIS vs placebo plus CT in patients with resectable NSCLC; here we report interim results for EFS and OS.

Methods: Patients with treatment-naïve resectable stage II–IIIA NSCLC eligible for platinum-doublet CT with no known *EGFR* mutations or *ALK* gene translocations were randomised (1:1) to either 3–4 cycles of neoadjuvant TIS 200 mg or placebo (IV Q3W) plus CT, then surgery and ≤8 cycles of adjuvant TIS 400 mg or placebo (IV Q6W). Dual primary endpoints were EFS by blinded independent central review and major pathological response by blinded independent pathology review. Secondary endpoints included pathological complete response, OS and safety.

Results: As of 21 Aug 2023 (median follow-up: 22.0 mo), 453 patients were randomized (TIS, n=226; placebo, n=227). Of these, 452 received neoadjuvant treatment (n=226 both arms [99.8%]), 421 (92.9%) completed neoadjuvant treatment (TIS, n=211 [93.4%]; placebo, n=210 [92.5%]), 363 (80.1%) had surgery (TIS, n=190 [84.1%]; placebo, n=173 [76.2%]), 315 (69.5%) received adjuvant treatment (TIS, n=168 [74.3%]; placebo, n=147 [64.8%]) and 207 (45.7%) completed adjuvant treatment (TIS, n=106 [46.9%]; placebo, n=101 [44.5%]). Median EFS or OS were not reached for either arm; however, a statistically significant difference in EFS (HR [95% CI], 0.56 [0.40–0.79]; 1-sided $P=0.0003$) and an OS benefit trend (HR [95% CI], 0.62 [0.39–0.98]; 1-sided $P=0.0193$) were observed favouring TIS. In the safety population (n=226 both arms), 224 (99.1%) patients on TIS vs 225 (99.6%) on placebo experienced ≥1 treatment-related adverse event (TRAE); 163 (72.1%) vs 150 (66.4%) experienced Grade ≥3 TRAEs and 35 (15.5%) vs 18 (8.0%) experienced serious TRAEs, respectively.

Conclusions: Neoadjuvant TIS plus CT with adjuvant TIS demonstrated a clinically meaningful and statistically significant benefit for EFS and an OS benefit trend vs placebo plus CT. Regimen safety was manageable and consistent with known treatment risks. These data support this combination as a new standard of care for patients with resectable NSCLC.